Compare FGBI & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | VANI |
|---|---|---|
| Founded | 1934 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 119.0M |
| IPO Year | 2014 | 2014 |
| Metric | FGBI | VANI |
|---|---|---|
| Price | $8.71 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 14.0K | ★ 211.9K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | $567.70 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.31 | $0.92 |
| 52 Week High | $11.02 | $1.92 |
| Indicator | FGBI | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 45.25 |
| Support Level | $8.24 | $1.26 |
| Resistance Level | $8.86 | $1.54 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 72.64 | 27.54 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana through several banking facilities. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and, to a lesser extent, consumer and multifamily loans. The company is engaged in a single line of business as a financial institution, which provides a full range of banking, financial, and trust services to state, county, and local government entities, individuals, and small and commercial businesses.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.